Covid-19 manufacturing roundup: AstraZeneca struggling to make planned vaccine deliveries to EU; J&J outlines plans to provide 100M doses of Covid vaccine in US as Pfizer, Moderna promise speedier delivery
As J&J neared FDA approval for its Covid-19 vaccine in the US, with plans to start shipping doses quickly, Novavax and AstraZeneca are hustling along right behind in an attempt to get into the game in North America. But AstraZeneca continues to roil the waters in Europe, where countries have been sorely disappointed over shortfalls in vaccine delivery.
That all got a little worse this week after Reuters reported that AstraZeneca told EU officials it would deliver less than half of the supply promised for Q2. That report was followed up quickly by AstraZeneca, which said it was pulling out the stops to get the full delivery in place. The EU has been stung by AstraZeneca’s reported shortfall during Q1, with less than half of the 90 million doses that were initially planned now expected.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,700+ biopharma pros reading Endpoints daily — and it's free.